Physician profile
Vedant Borad
NPI 1114314374
$1,518.65
in general payments reported to CMS, 2019-2025
13 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $469 · 2022: $513 · 2023: $243 · 2024: $110 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $467.57 | 2021-2022 | |
| Abbvie INC. | $318.26 | 2023-2025 | Natrelle Saline-Filled Breast Implants, Revolve |
| Medical Device Business Services, INC. | $299.99 | 2021 | |
| Sientra, INC. | $151.00 | 2021-2022 | |
| Kls-Martin L.P. | $99.09 | 2024-2025 | |
| Kerecis Limited | $41.33 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Mentor Worldwide LLC | $37.29 | 2023-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Pacira Pharmaceuticals Incorporated | $22.55 | 2021 | |
| Solventum Corporation | $21.98 | 2025 | Prevena, Activ.A.C., Promogran Prisma |
| Tela Bio, INC. | $18.40 | 2024 | Ovitex 2s |
| Kci USA, INC. | $15.08 | 2021 | |
| Polynovo North America LLC | $13.17 | 2021 | |
| Aroa Biosurgery Incorporated | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vedant Borad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.